Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program

E. Kneppers; H.M. Lokhorst; C.M. Eeltink; G. Huls; M.J. Kersten; J. Koedam; M.C. Minnema; M.H.J. van Oers; R.A.P. Raymakers; M.R. Schaafsma; E. Vellenga; P.W. Wijermans; S. Wittebol; P. Sonneveld; S. Zweegman

doi:10.3816/CLML.2010.n.020

Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program

E. Kneppers, H.M. Lokhorst, C.M. Eeltink, G. Huls, M.J. Kersten, J. Koedam, M.C. Minnema, M.H.J. van Oers, R.A.P. Raymakers, M.R. Schaafsma, E. Vellenga, P.W. Wijermans, S. Wittebol, P. Sonneveld, S. Zweegman

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	138-143
Journal	Clinical Lymphoma Myeloma and Leukemia
Volume	10
Issue number	2
DOIs	https://doi.org/10.3816/CLML.2010.n.020
Publication status	Published - 2010

Access to Document

10.3816/CLML.2010.n.020

Cite this

Kneppers, E., Lokhorst, H. M., Eeltink, C. M., Huls, G., Kersten, M. J., Koedam, J., Minnema, M. C., van Oers, M. H. J., Raymakers, R. A. P., Schaafsma, M. R., Vellenga, E., Wijermans, P. W., Wittebol, S., Sonneveld, P., & Zweegman, S. (2010). Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program. Clinical Lymphoma Myeloma and Leukemia, 10(2), 138-143. https://doi.org/10.3816/CLML.2010.n.020

Kneppers, E. ; Lokhorst, H.M. ; Eeltink, C.M. ; Huls, G. ; Kersten, M.J. ; Koedam, J. ; Minnema, M.C. ; van Oers, M.H.J. ; Raymakers, R.A.P. ; Schaafsma, M.R. ; Vellenga, E. ; Wijermans, P.W. ; Wittebol, S. ; Sonneveld, P. ; Zweegman, S. / Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program. In: Clinical Lymphoma Myeloma and Leukemia. 2010 ; Vol. 10, No. 2. pp. 138-143.

@article{904d8e3ac9354dcb83a4f6f3823d317b,

title = "Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program",

author = "E. Kneppers and H.M. Lokhorst and C.M. Eeltink and G. Huls and M.J. Kersten and J. Koedam and M.C. Minnema and {van Oers}, M.H.J. and R.A.P. Raymakers and M.R. Schaafsma and E. Vellenga and P.W. Wijermans and S. Wittebol and P. Sonneveld and S. Zweegman",

year = "2010",

doi = "10.3816/CLML.2010.n.020",

language = "Undefined/Unknown",

volume = "10",

pages = "138--143",

journal = "Clinical Lymphoma Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "2",

}

Kneppers, E, Lokhorst, HM, Eeltink, CM, Huls, G, Kersten, MJ, Koedam, J, Minnema, MC, van Oers, MHJ, Raymakers, RAP, Schaafsma, MR, Vellenga, E, Wijermans, PW, Wittebol, S, Sonneveld, P & Zweegman, S 2010, 'Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program', Clinical Lymphoma Myeloma and Leukemia, vol. 10, no. 2, pp. 138-143. https://doi.org/10.3816/CLML.2010.n.020

Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program. / Kneppers, E.; Lokhorst, H.M.; Eeltink, C.M.; Huls, G.; Kersten, M.J.; Koedam, J.; Minnema, M.C.; van Oers, M.H.J.; Raymakers, R.A.P.; Schaafsma, M.R.; Vellenga, E.; Wijermans, P.W.; Wittebol, S.; Sonneveld, P.; Zweegman, S.

In: Clinical Lymphoma Myeloma and Leukemia, Vol. 10, No. 2, 2010, p. 138-143.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Analysis of Efficacy and Prognostic Factors of Lenalidomide Treatment as Part of a Dutch Compassionate Use Program

AU - Kneppers, E.

AU - Lokhorst, H.M.

AU - Eeltink, C.M.

AU - Huls, G.

AU - Kersten, M.J.

AU - Koedam, J.

AU - Minnema, M.C.

AU - van Oers, M.H.J.

AU - Raymakers, R.A.P.

AU - Schaafsma, M.R.

AU - Vellenga, E.

AU - Wijermans, P.W.

AU - Wittebol, S.

AU - Sonneveld, P.

AU - Zweegman, S.

PY - 2010

Y1 - 2010

U2 - 10.3816/CLML.2010.n.020

DO - 10.3816/CLML.2010.n.020

M3 - Article

VL - 10

SP - 138

EP - 143

JO - Clinical Lymphoma Myeloma and Leukemia

JF - Clinical Lymphoma Myeloma and Leukemia

SN - 2152-2650

IS - 2

ER -